PHOTON-1  Design  Objective –SVR 12 with 2-sided 95% CI, descriptive analysis –Multivariate analyses of predictors of SVR 12 SOF + RBV, N= 114 SOF +

Slides:

Advertisements

Similar presentations

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.

Advertisements

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

CURRY  Design Open-label CURRY Study: SOF + RBV for HCV with liver cancer before transplantation ≥ 18 years Chronic HCV infection Any genotype HCV RNA.

Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:

Hepatitis web study Hepatitis web study Daclatasvir-Asunaprevir-Beclabuvir in Genotype 1 Cirrhotics UNITY-2 Study Phase 3 Treatment-Naïve and Treatment-Experienced.

COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

No HBV or HIV co-infection

C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.

SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.

Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.

W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.

TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +

SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.

No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.

ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.

Asselah T. AASLD 2015, Abs. 714 Randomisation 1:1 Open-label years HCV genotype 4 HCV RNA ≥ 1,000 IU/ml Naïve or pre-treated with PEG-IFN + RBV (Part.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-

 Design  Objective –Difference in SVR ≥ 40% between the 2 groups, 99% power SOF + RBV Placebo Randomisation 3 : 1* Double blind HCV infection Genotype.

SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.

Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)

Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.

 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.

SOF/VEL 400/100 mg qd N = 106 W12 > 18 years Chronic HCV infection Genotype 1-6 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis allowed*

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1

PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection

Retreatment study: SOF/VEL + RBV in prior NS5A failure - Phase II

Failure to achieve SVR on No HBV or HIV co-infection

QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3

SOF/VEL + GS-9857 in genotypes 1-6 Phase II

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

No HBV or HIV co-infection

GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II

ION-3 Study: LDV/SOF + RBV for naïve genotype 1

GS-US Study: SOF/VEL + GS in genotype 2, 3, 4 or 6 - Phase II

ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.

LDV/SOF ± RBV in genotype 3 or 6 – Phase 2

Presentation transcript:

PHOTON-1  Design  Objective –SVR 12 with 2-sided 95% CI, descriptive analysis –Multivariate analyses of predictors of SVR 12 SOF + RBV, N= 114 SOF + RBV, N = 68 Not randomised Open -label ≥ 18 years Chronic HCV infection Genotype 1, 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment-naïve (Genotype 1, 2, 3) or experienced (Genotype 2 and 3) Chronic HIV infection On ARV with HIV RNA < 50 c/ml, or not on ARV with CD4 > 500/mm 3 Compensated cirrhosis allowed PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection W12 W24 –SOF : 400 mg qd –RBV (bid dosing) : 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Genotype 1 Naïve Genotype 2, 3 Naïve Genotype 2, 3 Experienced Sulkowski M. JAMA 2014;312: SOF + RBV, N = 41

PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection Genotype 1 naïve N = 115 Genotype 2, 3 naïve N = 68 Genotype 2, 3 experienced N = 41 Mean age, years Female18%19%10% Race : white/black61% / 33%79% / 12%78% / 17% Body mass index, mean HCV genotype1a: 79% / 1b: 21%2: 38% / 3: 62%2: 59% / 3 : 41% IL28B CC genotype26.5%36.8%48.8% HCV RNA log 10 IU/ml, mean (SD) 6.6 ± ± ± 0.69 Cirrhosis4.4%10.3%24.4% CD4/mm 3, median On ARV98.2%89.7%95.1% ARV (%) : EFV ; ATV/r ; DRV/r ; RAL ; RPV38 ; 21 ; 13 ; 19 ; 633 ; 12 ; 28 ; 13 ; 841 ; 21 ; 5 ; 18 ; 5 Discontinued treatment, N11 (3 AE, 1 Failure)6 (3 AE)1 (1 AE) Returned for post-treatment W12 visit Baseline characteristics and patient disposition PHOTON-1 Sulkowski M. JAMA 2014;312:353-61

SVR 12 (HCV RNA < 25 IU/ml), % (95% CI) % Genotype 1 NaïveGenotype 2 and 3 NaïveGenotype 2 and 3 Experienced PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection PHOTON ( ) 82 Sub-genotype All ( ) 92.7 ( ) N 1a1b 94 GT2GT3 67 All GT2GT3 All Sulkowski M. JAMA 2014;312:353-61

Multivariate analysis of factors associated with SVR 12 in genotype 1 OR (95% CI)p Non black race2.87 ( )0.049 Genotype 1a3.42 ( )0.03 Completion of the 24 weeks of therapy17.54 ( )< Genotype 1 naïve N = 115 Genotype 2, 3 naïve N = 68 Genotype 2, 3 experienced N = 41 Virologic breakthrough 1 Non adherence 1 (genotype 2) Non adherence 0 Relapse In treatment completers In non-completers 19/103 (18%) 6/10 (60%) All genotype 3 11/61 (18%) 1/6 (17%) 1/40 (2.5%) 1/1 (100%) Mutations at relapse (deep sequencing) S282T or V321A L159F None 2 None 2 (genotype 3a) Virologic failures PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection PHOTON-1 Sulkowski M. JAMA 2014;312:353-61

PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection Genotype 1 naïve N = 115 Genotype 2, 3 naïve N = 68 Genotype 2, 3 experienced N = 41 AE leading to treatment discontinuation331 Serious adverse event8 (7%)5 (7%)1 (2%) AE occurring in ≥ 10% in either group Fatigue36%35%46% Insomnia13%21%20% Nausea16%18%15% Headache14%13%12% Irritability12%10%5% Cough12%6%10% Upper respiratory tract infection11%12% Diarrhea11%9%12% Dizziness6%1.5%12% Anemia11%9%7% Decreased hemoglobin < 10g/dl ; < 8.5 g/dl19% / 2%10% / 1.5%12% / 0 Adverse events, n (%) PHOTON-1 Sulkowski M. JAMA 2014;312:353-61

PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection  Summary In this open-label, non-randomised, uncontrolled study, patients with HCV who were co-infected with HIV had high rates of SVR 12 with the oral, IFN-free, combination of SOF + RBV –After 24 weeks of therapy for genotype 1 treatment-naïve and genotype 2 and 3 treatment-experienced –After 12 weeks of therapy for genotype 2 treatment-naïve Low rate of discontinuation for adverse events, however somewhat higher than in HCV monoinfected patients Confirmation of the high barrier to resistance of SOF (no resistance mutations at failure) Limitations –Underrepresentation of women and patients with cirrhosis –Absence of a control group Sulkowski M. JAMA 2014;312: PHOTON-1